Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial.
Obermann M, Nägel S, Ose C, Sonuc N, Scherag A, Storch P, Gaul C, Böger A, Kraya T, Jansen JP, Straube A, Freilinger T, Kaube H, Jürgens TP, Diener HC, Katsarava Z, Kleinschnitz C, Holle D. Obermann M, et al. Among authors: jansen jp. Lancet Neurol. 2021 Jan;20(1):29-37. doi: 10.1016/S1474-4422(20)30363-X. Epub 2020 Nov 24. Lancet Neurol. 2021. PMID: 33245858 Clinical Trial.
Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison.
Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ; Eletriptan and Cafergot Comparative Study Group. Diener HC, et al. Among authors: jansen jp. Eur Neurol. 2002;47(2):99-107. doi: 10.1159/000047960. Eur Neurol. 2002. PMID: 11844898 Clinical Trial.
Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain.
Webster L, Jansen JP, Peppin J, Lasko B, Irving G, Morlion B, Snidow J, Pierce A, Mortensen E, Kleoudis C, Carter E. Webster L, et al. Among authors: jansen jp. Pain. 2008 Jul 15;137(2):428-440. doi: 10.1016/j.pain.2007.11.008. Epub 2007 Dec 31. Pain. 2008. PMID: 18164818 Clinical Trial.
Efficacy and safety of lacosamide in painful diabetic neuropathy.
Ziegler D, Hidvégi T, Gurieva I, Bongardt S, Freynhagen R, Sen D, Sommerville K; Lacosamide SP743 Study Group. Ziegler D, et al. Diabetes Care. 2010 Apr;33(4):839-41. doi: 10.2337/dc09-1578. Epub 2010 Jan 12. Diabetes Care. 2010. PMID: 20067958 Free PMC article. Clinical Trial.
Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial.
Baron R, Jansen JP, Binder A, Pombo-Suarez M, Kennes L, Müller M, Falke D, Steigerwald I. Baron R, et al. Among authors: jansen jp. Pain Pract. 2016 Jun;16(5):600-19. doi: 10.1111/papr.12361. Epub 2015 Nov 11. Pain Pract. 2016. PMID: 26554630 Clinical Trial.
Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Distler O, Eich W, Dokoupilova E, Dvorak Z, Fleck M, Gaubitz M, Hechler M, Jansen JP, Krause A, Bendszus M, Pache L, Reiter R, Müller-Ladner U. Distler O, et al. Among authors: jansen jp. Arthritis Rheum. 2010 Jan;62(1):291-300. doi: 10.1002/art.25062. Arthritis Rheum. 2010. PMID: 20039417 Free article. Clinical Trial.
165 results